Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack recovery: could a 24-Hour hospital stay be just as safe?

NCT ID NCT06744322

Knowledge-focused Sponsor: Medical University Innsbruck Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether people who have a heart attack can be discharged from the hospital after about 24 hours instead of the usual 36 hours or more. Researchers want to see if early discharge is just as safe and does not increase the risk of death, another heart attack, or unplanned heart-related hospital visits. About 2,070 adults with uncomplicated heart attacks will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,070 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Uncomplicated acute myocardial infarction (NSTEMI and STEMI) diagnosed according to the 2023 acute coronary syndrome guidelines of the ESC * Age ≥ 18 years at time of consent * Invasive management strategy and in case of PCI successful intervention of the culprit lesion defined by post-interventional TIMI 3 flow * Ability to understand and willingness to sign and date written informed consent Exclusion Criteria: * Myocardial infarction complicated by cardiac arrest (out-of-hospital cardiac arrest/in-hospital cardiac arrest) * PCI-related complications (coronary perforation, side branch closure, inability to deliver stent/balloon, aortic dissection, allergic reaction grade ≥2, stroke/thromboembolism, access site complications including pseudoaneurysm, arteriovenous fistula, retroperitoneal hemorrhage and arterial dissection/occlusion or emboli) * Malignant arrhythmias including sustained ventricular arrhythmias and persistent bradycardia (\< 50 beats per minute due to sinus node or atrioventricular conduction system abnormalities, second- /third-degree atrioventricular block) after PCI * Ongoing hemodynamic instability (systolic blood pressure \<90 mmHg, elevated lactate concentrations, need for inotropes or vasopressors) * Ongoing respiratory instability defined by Killip class \>I (rales, pulmonary edema) * Ongoing quantitative disorders of consciousness (somnolence, sopor, coma) * Acute kidney injury defined by Kidney Disease Improving Global Outcomes (KDIGO) stages 2 and 3 * Pregnancy * Untreated critical non-culprit lesions requiring revascularization during index hospitalization not allowing fast discharge * Immobility/limited mobility or social circumstances that prevent fast discharge assessed by an interprofessional care team

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myocardial infarction (AMI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction myocardial infarction Non-ST Elevated Myocardial Infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myocardial infarction (AMI)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Academic Teaching Hospital Feldkirch

    RECRUITING

    Feldkirch, Vorarlberg, 6800, Austria

  • Cardinal Schwarzenberg Hospital Schwarzach

    NOT_YET_RECRUITING

    Schwarzach im Pongau, Schwarzach Im Pongau, 5620, Austria

  • Hospital Wiener Neustadt

    RECRUITING

    Wiener Neustadt, Lower Austria, 2700, Austria

  • Ludwig Maximilian University Munich

    NOT_YET_RECRUITING

    Munich, Bavaria, 81377, Germany

  • Medical University of Graz

    RECRUITING

    Graz, Styria, 8010, Austria

  • Medical University of Innsbruck

    RECRUITING

    Innsbruck, Tyrol, 6020, Austria

  • Paracelsus Medical University Salzburg

    RECRUITING

    Salzburg, State of Salzburg, 5020, Austria

  • University Teaching Hospital Wels-Grieskirchen

    RECRUITING

    Wels, Upper Austria, 4600, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.